1. Alpan O (2009) Identifying responders to Xolair (omalizumab) using eosinophilic esophagitis as a disease model. ClinicalTrials.gov identifier: NCT01040598. Available via http://clinicaltrials.gov . Accessed 2 April 2011
2. Fang JC (2005) A pilot study of the treatment of eosinophilic esophagitis with omalizumab. ClinicalTrials.gov identifier: NCT00123630. Available via http://clinicaltrials.gov . Accessed 2 April 2011
3. Menzella F, Facciolongo N, Castagnetti C, Simonazzi A, Zucchi L (2009) Omalizumab: when the non-responder is a late-responder. Eur Ann Allergy Clin Immunol 41(5):155–9
4. Rafi A, Do LT, Katz R, Sheinkopf LE, Simons CW, Klaustermeyer W (2010) Effects of omalizumab in patients with food allergy. Allergy Asthma Proc 31(1):76–83
5. Stein ML, Collins MH, Villanueva JM, Kushner JP, Putnam PE, Buckmeier BK, Filipovich AH, Assa'ad AH, Rothenberg ME (2006) Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. J Allergy Clin Immunol 118(6):1312–9